Metylfenidat Actavis (Methylphenidate Hydrochloride)

Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their concentrations at synaptic junctions. This enhances neurotransmission in brain circuits that control attention, impulse control, and wakefulness, thereby improving concentration and reducing symptoms of hyperactivity or sleepiness. Its pharmacologic action is rapid and reversible.

The appropriate dose of Metylfenidat Actavis is individualized by the prescribing clinician based on the patient’s age, weight, clinical response, and tolerability. Dosage adjustments are made during treatment to achieve optimal symptom control while minimizing adverse effects. Patients should follow the prescriber’s instructions and not alter the dose without medical guidance.

Safety data for methylphenidate use in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs possible risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider, who can assess individual risk factors.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Metylfenidat Actavis. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details, and assists with any necessary import documentation.

Metylfenidat Actavis contains methylphenidate, a stimulant that primarily blocks dopamine and norepinephrine reuptake. Compared with amphetamine‑based stimulants, methylphenidate generally has a shorter half‑life and may present a different side‑effect profile, such as a lower propensity for appetite suppression in some patients. Choice of therapy depends on individual response, tolerability, and clinician preference.

Metylfenidat Actavis should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture, heat, and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label. If the tablets become discolored or damaged, discard them according to local regulations.

The medication is taken orally, usually with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with a glass of water and not chewed, crushed, or broken unless specifically instructed. Dosing times are often scheduled in the morning and, if needed, a second dose in the early afternoon to avoid interference with sleep.

Serious adverse events, although uncommon, can include cardiovascular complications such as hypertension, arrhythmias, or myocardial infarction, as well as psychiatric effects like new or worsening psychosis, severe agitation, or manic episodes. Rarely, allergic reactions such as anaphylaxis may occur. Patients should seek immediate medical attention if they experience chest pain, severe mood changes, or signs of an allergic reaction.

Metylfenidat Actavis is contraindicated in individuals with known hypersensitivity to methylphenidate or any component of the formulation, as well as patients who have taken monoamine oxidase inhibitors within the past 14 days. It should also be avoided in patients with serious cardiovascular disorders, uncontrolled hypertension, hyperthyroidism, or a history of severe psychiatric conditions unless closely monitored by a specialist.